Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Related Citations for PubMed (Select 24377544)

1.

Reduction of proliferation and induction of apoptosis are associated with shrinkage of head and neck squamous cell carcinoma due to neoadjuvant chemotherapy.

Sarkar S, Maiti GP, Jha J, Biswas J, Roy A, Roychoudhury S, Sharp T, Panda CK.

Asian Pac J Cancer Prev. 2013;14(11):6419-25.

2.

p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.

Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P.

J Clin Oncol. 2000 Apr;18(7):1465-73.

PMID:
10735894
3.

Pharmacodynamics of taxol in human head and neck tumors.

Gan Y, Wientjes MG, Schuller DE, Au JL.

Cancer Res. 1996 May 1;56(9):2086-93.

4.
5.

A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.

Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, Spange S, Nonnenmacher F, Fetz V, Ginter T, Reichardt S, Liebmann C, Schneider G, Krämer OH.

Oncotarget. 2012 Jan;3(1):31-43.

6.

CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.

Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J, Zhu H, Wang Z, Li J, Wang L, Wang B, Ren G, Ji T, Tu W, Yang X, Qiu W, Mao L, Zhang Z, Chen W.

PLoS One. 2011;6(10):e26399. doi: 10.1371/journal.pone.0026399. Epub 2011 Oct 31.

7.

Isoalantolactone inhibits UM-SCC-10A cell growth via cell cycle arrest and apoptosis induction.

Wu M, Zhang H, Hu J, Weng Z, Li C, Li H, Zhao Y, Mei X, Ren F, Li L.

PLoS One. 2013 Sep 30;8(9):e76000. doi: 10.1371/journal.pone.0076000. eCollection 2013.

8.

Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.

Mishra PB, Lobo AS, Joshi KS, Rathos MJ, Kumar GA, Padigaru M.

J Transl Med. 2013 Feb 18;11:42. doi: 10.1186/1479-5876-11-42.

9.
10.

Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.

Lee DW, Park SW, Park SY, Heo DS, Kim KH, Sung MW.

Head Neck. 2004 Aug;26(8):706-15.

PMID:
15287038
11.

Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt.

Kuo SZ, Blair KJ, Rahimy E, Kiang A, Abhold E, Fan JB, Wang-Rodriguez J, Altuna X, Ongkeko WM.

BMC Cancer. 2012 Nov 24;12:556. doi: 10.1186/1471-2407-12-556.

12.

Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.

Uehara T, Kanazawa T, Mizukami H, Uchibori R, Tsukahara T, Urabe M, Kume A, Misawa K, Carey TE, Suzuki M, Ichimura K, Ozawa K.

Cancer Sci. 2014 Jan;105(1):72-80. doi: 10.1111/cas.12315. Epub 2013 Dec 1.

13.

Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.

Van Waes C, Allen CT, Citrin D, Gius D, Colevas AD, Harold NA, Rudy S, Nottingham L, Muir C, Chen Z, Singh AK, Dancey J, Morris JC.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):447-54. doi: 10.1016/j.ijrobp.2009.05.037. Epub 2009 Oct 30.

14.

Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.

Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, Sanchez JJ, Ballestin C, Diez A, Sanchez-Verde L, Alameda F, Sanchez-Cespedes M.

Clin Cancer Res. 2004 Dec 15;10(24):8486-92.

15.

LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: clinical and prognostic implications.

Ghosh S, Ghosh A, Maiti GP, Mukherjee N, Dutta S, Roy A, Roychoudhury S, Panda CK.

Mol Cancer. 2010 Mar 12;9:58. doi: 10.1186/1476-4598-9-58.

16.

VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma.

Santos CR, Rodríguez-Pinilla M, Vega FM, Rodríguez-Peralto JL, Blanco S, Sevilla A, Valbuena A, Hernández T, van Wijnen AJ, Li F, de Alava E, Sánchez-Céspedes M, Lazo PA.

Mol Cancer Res. 2006 Mar;4(3):177-85.

17.

Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma.

Blons H, Cabelguenne A, Carnot F, Laccourreye O, de Waziers I, Hamelin R, Brasnu D, Beaune P, Laurent-Puig P.

Int J Cancer. 1999 Aug 20;84(4):410-5.

PMID:
10404095
18.

[The effect of the microenvironment of head and neck cancers on tumor progression].

Lukits J.

Magy Onkol. 2009 Mar;53(1):51-9. doi: 10.1556/MOnkol.53.2009.1.8. Hungarian.

19.

MicroRNA expression profile in head and neck cancer: HOX-cluster embedded microRNA-196a and microRNA-10b dysregulation implicated in cell proliferation.

Severino P, Brüggemann H, Andreghetto FM, Camps C, Klingbeil Mde F, de Pereira WO, Soares RM, Moyses R, Wünsch-Filho V, Mathor MB, Nunes FD, Ragoussis J, Tajara EH.

BMC Cancer. 2013 Nov 9;13:533. doi: 10.1186/1471-2407-13-533.

20.

Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent.

Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis J, Romkes M, Weissfeld JL.

Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2429-37. doi: 10.1158/1055-9965.EPI-11-0520. Epub 2011 Sep 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk